Biomarkers in Diagnosis and Treatment of Pulmonary Disease

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Disease Biomarker".

Deadline for manuscript submissions: 30 July 2024 | Viewed by 1414

Special Issue Editors

1. Department of Pathology, General Hospital of Thessaloniki 'Georgios Papanikolaou', Thessaloniki, Greece
2. Laboratory of Histology-Embryology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
Interests: asthma; lung cancer; biomarkers; airway remodeling
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Pulmonary Department, General Hospital of Thessaloniki 'Georgios Papanikolaou', Aristotle University of Thessaloniki, Thessaloniki, Greece
Interests: asthma; bronchoscopy; lung cancer; biologic agents

Special Issue Information

Dear Colleagues,

The lungs and airways are affected by several pathologies such as inflammation, infection and cancer. We know that the combination of biomarkers yields more information when analyzing the association between systemic inflammation and lung function. Indeed, pulmonary biomarkers may be useful in diagnosis, predicting disease progression, indicating disease instability and predicting response to current therapies and novel therapies, many of which are now in development.

In addition, studies have shown that abnormally developed lung structure and function may contribute as susceptibility factors in several adult lung diseases such as COPD, cystic fibrosis and asthma, caused by many etiologies, including genetic–environmental interactions. Thus, lung development and pathogenesis are connected, indicating the need to identify more biomarkers at early stages.

Ιn this Special Issue, we would like to welcome the submission of original research studies (either clinical or basic), meta-analysis and state-of-the-art reviews related to pulmonary diseases. Focus will be placed on the identification of biomarkers in the context of precision medicine for patients with pulmonary diseases. Within the scope of these terms, this Special Issue aims to collate novel data so as to move the current knowledge of pulmonary diseases forward.

Dr. Kelly Domvri
Dr. Konstantinos Porpodis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • asthma
  • obstructive disease
  • cancer
  • pulmonary fibrosis
  • airway remodeling
  • inflammation

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1239 KiB  
Article
Prognostic Value of Serum Biomarkers in Patients with Idiopathic Pulmonary Fibrosis in Relation to Disease Progression
by Kalliopi Domvri, Ioannis Organtzis, Apostolos Apostolopoulos, Evangelia Fouka, Theodoros Kontakiotis and Despoina Papakosta
J. Pers. Med. 2023, 13(9), 1307; https://doi.org/10.3390/jpm13091307 - 26 Aug 2023
Cited by 4 | Viewed by 1146
Abstract
Background: The aim of this present study was to determine serum biomarker levels and their correlation with respiratory function and the clinical course of patients with idiopathic pulmonary fibrosis (IPF). Materials and Methods: This study included 72 IPF patients, according to the ATS/ERS [...] Read more.
Background: The aim of this present study was to determine serum biomarker levels and their correlation with respiratory function and the clinical course of patients with idiopathic pulmonary fibrosis (IPF). Materials and Methods: This study included 72 IPF patients, according to the ATS/ERS criteria, in whom antifibrotic treatment was initiated. Blood samples were taken, and serum biomarkers, such as KL-6, SP-D, CCL18, CXCL13, VEGF-A, IL-8, IGFBP-1, IGFBP-2, IGFBP-7 and ICAM-1 were measured using ELISA methodology. Pulmonary function tests (FVC, TLC, DLCO-% pred) were determined at baseline and after 12 and 24 months and analyzed in correlation with the biomarkers. Results: The majority of patients (mean age 72 ± 6 years) were men (83%). The FVC and DLCO values at the 12-month follow-up were found to be statistically decreased in deceased patients (p < 0.05). The SP-D (p < 0.001) and the IGFBP-1 (p = 0.021) levels were found to be increased at the 1-year follow-up in deceased patients, and similarly, the SP-D (p = 0.005) and ICAM-1 (p = 0.043) levels at the 2-year follow-up. A chi-square test revealed that 70% of the category IV GAP index was found with cut-off elevated levels of a biomarker combination (KL-6, SP-D, VEGF-A) from the ROC curve analysis (p < 0.05). Conclusion: This study provides evidence, for the first time in a Greek population, of the possibility of using a combination of KL-6, SP-D, and VEGF-A serum levels along with the GAP index. Full article
(This article belongs to the Special Issue Biomarkers in Diagnosis and Treatment of Pulmonary Disease)
Show Figures

Figure 1

Back to TopTop